Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18886286 | 1.00 | SMN1; SMN2 (0.69) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL1668653 | 0.99 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL25330859 | 0.96 | LMNA (0.63) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL25195645 | 0.96 | LMNA (0.63) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL25372019 | 0.94 | LMNA (0.62) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL24710032 | 0.94 | LMNA (0.60) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL25030646 | 0.93 | LMNA (0.59) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL25029578 | 0.92 | LMNA (0.62) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL19384711 | 0.92 | LMNA (0.58) | SMN1; SMN2LMNAHTTL3MBTL1MAPT | |
| SCHEMBL24038721 | 0.92 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAHTTL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107896-A9 | TREATMENT OF FGG RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024137663-A2 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024118979-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240018523-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018523-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023250327-A1 | TREATMENT OF GPAM RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230295630-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023178264-A2 | TREATMENT OF HGFAC RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178144-A2 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295630-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023107896-A1 | TREATMENT OF FGG RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-109069569-B | Protein conjugates using fatty acid derivatives and methods of making the same | 韩美药品株式会社 | 2023-02-14 | — | — | CN | disclosed |
| WO-2022271552-A1 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022266037-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266042-A1 | TREATMENT OF MST1R RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266132-A1 | TREATMENT OF PLIN1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266045-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022261005-A1 | TREATMENT OF ANGPTL4 RELATED DISEASES | EMPIRICO INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022140365-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-111164128-A | Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and method for preparing the same | 韩美药品株式会社 | 2020-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018523-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | CSGALNACT1, B3GAT3, UGGT1 | SMN1; SMN2 363/4885LMNA 1623/4885HTT 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.